Press Releases

2022

September 21, 2022
Neurona Therapeutics Presents Clinical Case Study from First Human Trial of Regenerative Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

June 29, 2022
Neurona Therapeutics Announces Initial Subject Dosed in First Clinical Trial of Regenerative Human Cell Therapy, NRTX-1001, in Adults with Drug-Resistant Focal Epilepsy

June 17, 2022
Neurona Therapeutics to Present Preclinical Data Supporting Regenerative Cell Therapy, NRTX-1001, in Clinical Development for Chronic Focal Epilepsy, at the ISSCR 2022 Annual Meeting

May 26, 2022
Neurona Therapeutics Awarded $8 Million by California Institute for Regenerative Medicine (CIRM) to Support Phase 1/2 Clinical Trial of NRTX-1001 for Chronic Focal Epilepsy 

April 4, 2022
Neurona Therapeutics to Present at the Locust Walk Stem Cell Tx Conference

April 1, 2022
Neurona Therapeutics Presents Preclinical Data at the American Academy of Neurology (AAN) Annual Meeting from Lead Cell Therapy Candidate, NRTX-1001, Being Evaluated in a Phase 1/2 Clinical Trial for Chronic Focal Epilepsy

January 5, 2022
Neurona Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

2021

December 13, 2021
Neurona Therapeutics Announces C-Suite Leadership Team

December 3, 2021
Neurona Therapeutics to Present New Preclinical Data and Clinical Trial Plans for Lead Neural Cell Therapy Program, NRTX-1001, at the Annual Meeting of the American Epilepsy Society

November 18, 2021
Neurona Therapeutics to Present at the Piper Sandler 33rd Annual Healthcare Conference

November 8, 2021
Neurona Therapeutics Presents Preclinical Data from Lead Cell Therapy Candidate NRTX-1001 at Neuroscience 2021.

November 4, 2021
Neurona Therapeutics Receives IND Clearance to Initiate Phase 1/2 Clinical Trial of Neural Cell Therapy NRTX-1001 in Chronic Focal Epilepsy Patients.

October 20, 2021
Neurona Therapeutics Appoints Brad Margus to its Board of Directors

June 22, 2021
Neurona Therapeutics Raises $41.5M to Advance Neural Network-Rebalancing Cell Therapies for the Treatment of Epilepsy and other Neurological Disorders

June 16, 2021
Neurona Therapeutics Presents Clinical Development Plan for Lead Cell Therapy Program at the 16th Conference on Antiepileptic Drug and Device Trials (AEDD TRIALS XVI

April 19, 2021
Neurona Therapeutics Presents Preclinical Data from Lead Inhibitory Cell Therapy Program, Demonstrating Significant Seizure Suppression in Model of Focal Epilepsy

2019-2015

October 31, 2019
Neurona Therapeutics awarded a $4.8M translational grant from CIRM to advance epilepsy program to the pre-IND stage

December 14, 2017
CIRM Discovery Quest Award program: Neurona Therapeutics receives funding

December 1, 2015
Neurona Therapeutics Launches with $23.5 Million in Series A Funding to Repair Damaged Neural Circuits